Melody Cobleigh is an Oncology physician affiliated with Rush University Medical Center. OpenAlex indexes 212 publications with 21,489 citations (h-index 47); ClinicalTrials.gov lists 4 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1725 W Harrison St
Suite 1010
Chicago, IL 606123841
Telephone
312-942-5904Registry record last updated 14 Apr 2011.
Clinical trials
- Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy
Sponsor: National Cancer Institute (NCI)
- Paclitaxel With or Without Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
Sponsor: Eastern Cooperative Oncology Group
- Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women Receiving Tamoxifen for Breast Cancer
Sponsor: Eastern Cooperative Oncology Group
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- MACROGENICS, INC.Program year20211 payment
- Gilead Sciences, Inc.Program year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
79.8%Kinase inhibitor34.1%Kisqali85%Ibrance15%Part D<11 patientsAromatase Inhibitor32.1%Anastrozole78%Letrozole22%Part D<11 patients+ 2 more classes in this area
Metabolism & gastrointestinal
10.8%Serotonin-3 Receptor Antagonist10.8%Ondansetron Hcl100%Part D≥18 patientsSensory organs
5.2%Corticosteroid5.2%Dexamethasone100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 1987–1987 per NIH RePORTER. The latest:
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Christopher Goetz, MD
Rush University Medical Center
Theodore Pincus, MD
Rush University Medical Center
Christopher Seder, MD
Rush University Medical Center
Neelum Aggarwal, MD
Rush University Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”